Bridgeway Capital Management’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
Other funds holding AKBA
Bridgeway Capital Management's AKBA Position: Q3 2026 in Review
Bridgeway Capital Management opened a new position in Akebia Therapeutics (AKBA) in Q3 2026: 100,000 shares worth $92K. The stake represents ﹤0.01% of the portfolio and ranks #1135 among its holdings. This is a return to the name: Bridgeway Capital Management previously reported a position in AKBA as recently as Q1 2017.
Bridgeway Capital Management first reported a position in AKBA in Q1 2015 and has held it in 10 quarters since. The position peaked at $1.25M in Q4 2015. 156 funds tracked by Wall St. Rank hold AKBA as of Q3 2026.
- Bridgeway Capital Management held 100,000 shares of Akebia Therapeutics worth $92K as of Q3 2026.
- Akebia Therapeutics was a new Bridgeway Capital Management position in Q3 2026.
- Akebia Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q3 2026, its #1135 holding.
- Bridgeway Capital Management first reported a position in Akebia Therapeutics in Q1 2015 and has held it in 10 quarters since.
- Bridgeway Capital Management's Akebia Therapeutics position peaked at $1.25M in Q4 2015.
- 156 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2026.
Based on Bridgeway Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.